Immunotherapy of cancer through targeting of the p53 tumor antigen.
The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or autoimmune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for the immunotherapy of cancer.
Zwaveling
Sander
S
Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Tumor Immunology Group, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Van der Burg
Sjoerd H
SH
Menon
Anand G
AG
Melief
Cornelis J M
CJ
Offringa
Rienk
R
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000378:metabolism*; D015551:Autoimmunity; D015179:Colorectal Neoplasms / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D000951:Antigens, Neoplasm; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2